RJA
CME icon

Raymond James & Associates’s CME Group CME Stock Holding History

Raymond James & Associates’s Portfolio CME Stock Details CME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,100
Closed -$9.81K – 3911
2022
Q4 		$9.81K Sell
15,100
-15,100
-50% -$2.62M ﹤0.01% 3847
2022
Q3 		$13K Hold
30,200
– – ﹤0.01% 3835
2022
Q2 		$21K Buy
30,200
+10,900
+56% +$2.31M ﹤0.01% 3870
2022
Q1 		$27K Buy
19,300
+3,300
+21% +$775K ﹤0.01% 3973
2021
Q4 		$35K Sell
16,000
-2,500
-14% -$550K ﹤0.01% 3987
2021
Q3 		$19K Sell
18,500
-16,600
-47% -$3.36M ﹤0.01% 4007
2021
Q2 		$29K Buy
35,100
+400
+1% +$84.5K ﹤0.01% 3954
2021
Q1 		$24K Sell
34,700
-900
-3% -$177K ﹤0.01% 3906
2020
Q4 		$18K Sell
35,600
-15,700
-31% -$2.67M ﹤0.01% 3693
2020
Q3 		$37K Sell
51,300
-22,900
-31% -$3.86M ﹤0.01% 3467
2020
Q2 		$56K Buy
74,200
+6,400
+9% +$1.15M ﹤0.01% 3366
2020
Q1 		$320K Buy
67,800
+19,100
+39% +$3.8M ﹤0.01% 2723
2019
Q4 		$32K Sell
48,700
-900
-2% -$185K ﹤0.01% 3584
2019
Q3 		$283K Sell
49,600
-1,500
-3% -$313K ﹤0.01% 3046
2019
Q2 		$89K Sell
51,100
-23,400
-31% -$4.31M ﹤0.01% 3430
2019
Q1 		$28K Sell
74,500
-5,400
-7% -$955K ﹤0.01% 3512
2018
Q4 		$214K Buy
79,900
+36,400
+84% +$6.72M ﹤0.01% 3083
2018
Q3 		$274K Sell
43,500
-41,300
-49% -$6.95M ﹤0.01% 3095
2018
Q2 		$431K Buy
84,800
+48,700
+135% +$7.95M ﹤0.01% 2783
2018
Q1 		$426K Sell
36,100
-15,500
-30% -$2.47M ﹤0.01% 2664
2017
Q4 		$253K Sell
51,600
-62,300
-55% -$8.87M ﹤0.01% 2926
2017
Q3 		$550K Buy
113,900
+11,200
+11% +$1.41M ﹤0.01% 2427
2017
Q2 		$270K Buy
102,700
+49,500
+93% +$5.92M ﹤0.01% 2787
2017
Q1 		$88K Sell
53,200
-400
-0.7% -$48.1K ﹤0.01% 3083
2016
Q4 		$161K Buy
53,600
+8,300
+18% +$924K ﹤0.01% 2937
2016
Q3 		$66K Buy
45,300
+400
+0.9% +$41.8K ﹤0.01% 3058
2016
Q2 		$40K Buy
44,900
+6,800
+18% +$643K ﹤0.01% 2889
2016
Q1 		$35K Buy
+38,100
New +$3.47M ﹤0.01% 2817

Other funds holding CME

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Raymond James & Associates's CME Position: Q3 2024 in Review

Raymond James & Associates reduced its CME Group (CME) stake by 5.4% in Q3 2024, selling an estimated $33.9M and leaving 2,865,142 shares worth $632M. The position accounts for 0.39% of the portfolio, ranked #44.

Raymond James & Associates first reported a position in CME in Q2 2013 and has held it in 46 quarters since. 1,390 funds tracked by Wall St. Rank hold CME as of Q3 2024.

  • Raymond James & Associates held 2,865,142 shares of CME Group worth $632M as of Q3 2024.
  • Raymond James & Associates sold 164,003 CME Group shares in Q3 2024, an estimated $33.9M.
  • CME Group made up 0.39% of Raymond James & Associates's portfolio in Q3 2024, its #44 holding.
  • Raymond James & Associates first reported a position in CME Group in Q2 2013 and has held it in 46 quarters since.
  • 1,390 funds tracked by Wall St. Rank held CME Group as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.